The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease
Open accessAbstract
Context: The cardiovascular benefits of semaglutide are established; however, its effects on surrogate vascular markers and liver function are not known. Objective: To investigate the effects of semaglutide on vascular, endothelial, and liver function in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods: Overall, 75 consecutive subjects with T2DM and NAFLD were enrolled: 50 patients received semaglutide 1 mg (treatment group) and 25 patients received dipeptidyl peptidase 4 inhibitors (control group). All patients underwent a clinical, vascular, and hepatic examination with Fibroscan elastography at 4 and 12 months after inclusion in the study. Results: Treatment with semaglutide resulted in a reduction of Controlled Attenuation Parameter (CAP) score, E fibrosis score, NAFLD fibrosis score, Fibrosis-4 (FIB-4) score and perfused boundary region (PBR) at 4 and at 12 months (P < .05), contrary to controls. Patients treated with semaglutide showed a greater decrease of central systolic blood pressure (SBP) (−6% vs −4%, P = .048 and −11% vs −9%, P = .039), augmentation index (AIx) (−59% vs −52%, P = .041 and −70% vs −57%, P = .022), and pulse wave velocity (PWV) (−6% vs −3.5%, P = .019 and −12% vs −10%, P = .036) at 4 and at 12 months, respectively. In all patients, ΔPWV and ΔPBR were correlated with a corresponding reduction of CAP, E fibrosis, NAFLD fibrosis, and FIB-4 scores. Conclusion: Twelve-month treatment with semaglutide simultaneously improves arterial stiffness, endothelial function, and liver steatosis and fibrosis in patients with T2DM and NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs, particularly semaglutide, have been shown to reduce liver steatosis and improve markers of liver inflammation and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.34, 35, 36”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 1×
“Treatment with liraglutide or exendin-4 increased endothelial NO synthase (eNOS) phosphorylation and NO production in a 5 ′ AMP-activated protein kinase (AMPK)-dependent manner [27, 28].”
BackgroundRetractedChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) is now considered the most frequent liver disease worldwide, with its global prevalence reaching up to 32.4% [1].”
BackgroundInfluentialA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“…to our results due to the use of Fibroscan, was a 72-week, double-blind phase 2 trial, involving patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3, where patients were assigned to once-daily semaglu-tide at a dose of 0.1, 0.2, or 0.4 mg or corresponding placebo [34].”
MethodInfluentialBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“GLP-1R expression has been detected in mouse mesenteric or coronary arteries in immunohistochemistry studies utilizing GLP-1R antibodies; however, their validity has been proven to be nonspecific in some cases [24].”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 1×
“On the other hand, in human models, Western blotting has confirmed GLP-1R protein expression in human umbilical vein endothelial cells (HUVECs) [25], but in human heart samples, full-length GLP1-R mRNA transcripts have not been detected [26].”
BackgroundLoomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533 · cited 1×
“…of 27 kg/m² were assigned to semaglutide 2.4 mg or placebo, no statistically significant difference between the 2 groups in the proportion of patients who had an improvement in liver fibrosis of 1 stage or more was noted after 48 weeks, and the same applied for the endpoint of NASH resolution [33].”
InfluentialGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 1×
“GLP-1 ligands are able to promote the phosphorylation of AKT, an effect that subsequently triggers the postreceptor signaling cascade downstream of insulin receptor substrate-2 (IRS-2), leading to reduced storage of hepatocyte triglycerides and, therefore, reduced hepatic steatosis [39].”
BackgroundLekakis, J., Abraham, P., Balbarini, A., Blann, A., Boulanger, C. M., Cockcroft, J., Cosentino, F., Deanfield, J., Gallino, A., Ikonomidis, I., et al. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711398179 · Cited by 315 · cited 1×
“However, due to the detrimental effects of diabetes on the endothelium early in the course of the disease, endothelial dysfunction has been considered a reliable predictor of cardiovascular disease in recent years [7].”
BackgroundSelf-citation
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 75
“In addition, another study shows that treatment with semaglutide resulted in a reduction in the Controlled Attenuation Parameter (CAP) score, E fibrosis score, NAFLD fibrosis score, and fibrosis-4 (FIB-4) score [117,118].”
Self-citationMechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
“Semaglutide treatment for 12 months reduced arterial stiffness, improved endothelial function, and decreased liver steatosis and fibrosis in T2DM patients with MASLD, indicating concurrent cardiovascular benefits [76].”
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 15
“An Rct involving 50 patients [51] indicated a significant improvement in liver fibrosis, whereas two other Rcts reported non-significant improvements compared with placebo [48].”
Bołdys, A., Bułdak, Ł., Nicze, M., & Okopień, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125883 · Cited by 9
“These outcomes are comparable to those reported for semaglutide in patients with NAFLD and type 2 diabetes mellitus, where CAP values decreased from 319 ± 37 to 283 ± 46 dB/m ( p 0.001) [21].”
Influential
Metadata
- Authors
- Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., Pililis, S., Malandris, K., Tsapas, A., Siasos, G., Ikonomidis, I., & Lambadiari, V.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- Clinical Research and Evidence-Based Medicine Unit, Aristotle University of Thessaloniki , 54124 Thessaloniki , Greece
- Corresponding author
- Lambadiari, Vaia
- ORCID
- Korakas, Emmanouil
- Kountouri, Aikaterini
- Pavlidis, George
- Oikonomou, Evangelos
- Vrentzos, Emmanouil
- Michalopoulou, Eleni
- Tsigkou, Vasiliki
- Katogiannis, Konstantinos
- Pliouta, Loukia
- Balampanis, Konstantinos
- Pililis, Sotirios
- Malandris, Konstantinos
- Tsapas, Apostolos
- Siasos, Gerasimos
- Ikonomidis, Ignatios
- Lambadiari, Vaia
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2024-07-01
- Volume
- 8
- Issue
- 8
- Pages
- bvae122-bvae122
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC11228545
- OpenAlex
- W4400423778
- Cited by
- 18
- References
- 50
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 1
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the Endocrine Society (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, type 2 diabetes, non-alcoholic fatty liver disease, arterial stiffness, endothelial function, liver fibrosis, hepatic steatosis, pulse wave velocity, augmentation index, controlled attenuation parameter, DPP-4 inhibitors, cardiovascular risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease. https://app.cochat.ai/papers/10.1210/jendso/bvae122
- The paper
- Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., Pililis, S., Malandris, K., Tsapas, A., Siasos, G., Ikonomidis, I., & Lambadiari, V. (2024). Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease. Journal of the Endocrine Society. https://doi.org/10.1210/jendso/bvae122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.